ZW251 — Investigational Agent
Antibody-Drug Conjugate · Phase 1 · Zymeworks
Mechanism of Action
A GPC3-directed antibody-drug conjugate delivering a topoisomerase I inhibitor payload to glypican-3-expressing tumors, notably hepatocellular carcinoma, with cleavable-linker-enabled bystander activity.
Investigational Indications
- Hepatocellular carcinoma
- GPC3-expressing advanced solid tumors